Ausper Biopharma Co., Ltd.

This Phase 2 trial tests an injection called AHB-137 in 60 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the drug can lower virus levels enough that patients can safely stop all treatment. The study will check if the virus stays undetec…

This Phase 2 trial tests a new drug called AHB-137, given alongside a hepatitis B vaccine or peginterferon, in 200 adults with chronic hepatitis B who are already on antiviral pills. The goal is to see if the combination can clear the hepatitis B surface antigen (HBsAg) from the …

This early-stage study tests a single injection of AHB-137 in 32 people with chronic hepatitis B, some with mild to moderate liver dysfunction and some with normal liver function. Researchers will measure how the drug moves through the body and check for safety issues. The goal i…

This study checks if people with chronic hepatitis B who got better with the drug AHB-137 stay virus-free over time. About 200 adults who already responded to AHB-137 will be followed for years. The goal is to see if the virus stays undetectable and if liver health improves witho…

This phase 2 trial tests an injection called AHB-137 in adults with chronic hepatitis B who have not yet received treatment. The study compares AHB-137 to a placebo to see if it can lower the amount of hepatitis B virus in the blood and reduce a key marker of infection (HBsAg). P…

This early-stage study tests an injection called AHB-171 in healthy volunteers and people with chronic hepatitis B. The main goals are to check safety, how the body processes the drug, and whether it shows any signs of controlling the virus. About 110 participants will be enrolle…

This Phase 2 trial tests an injection called AHB-171 in 138 people with chronic hepatitis B. The goal is to see if it can lower hepatitis B surface antigen and viral DNA to very low levels, potentially leading to a functional cure. Participants include those who have never been t…